|display ongoing studies|
||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results||deaths E||clinical improvement E||death or ventilation E|
COVID-19 mild to moderate meta-analysis
|RCT||interferon / TFF2||standard of care||COVID-19 mild to moderate||some concern||40/40||inconclusive|
|RCT||IFN gamma||standard of care||COVID-19 mild to moderate||high||30/33||conclusif|
|RCT||peginterferon||placebo||COVID-19 mild to moderate||some concern||60/60||inconclusive|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).